Acknowledgments
Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet 2021; 398: 2258–76—In this Article, Prof Teresa Lambe should have been included in the author list, and her affiliations should have been Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK and NIHR Oxford Biomedical Research Centre, Oxford, UK. Jonathan Kwok's degree should have been MB BChir. In table 9, the Day 0 SARS-CoV-2 anti-spike IgG should have read 1443 (1051–1982; n=23) for the ChAd/ChAd-primed group who received BNT as a third dose. The appendix has been corrected. These corrections have been made to the online version as of Dec 16, 2021, and the printed version is correct.